Predictors of Long-Term Evolution in Long COVID; 4-Year Follow-Up. (BioICOPER Follow-up Study)

Recruiting now

Conditions studied: Persistent COVID Condition

In brief

Long COVID (persistent COVID) represents a major global health challenge due to its high prevalence (approximately 7%), significant impact on quality of life, and socioeconomic burden. Despite extensive research, diagnostic tools to objectively identify or predict long COVID evolution are still lacking. The BioICOPER Follow-up Study aims to analyze the influence of biomarker evolution on clinical symptomatology (particularly chronic fatigue) and vascular health after four years of follow-up among 400 participants previously included in the original BioICOPER cohort. Advanced proteomic analysis, vascular function assessment, and machine-learning-based predictive modeling will be used to identify biomarkers associated with disease progression, stratified by sex. This project will contribute to personalized clinical management of long COVID and improved diagnostic and therapeutic strategies in primary care.

Key facts

Study ID

NCT07295483

Run by

Instituto de Investigación Biomédica de Salamanca

People needed

400

Starts

2026-02-09

Expected to finish

2029-06-01

Last updated by the study team

2026-03-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults ≥18 years old.
• Confirmed previous SARS-CoV-2 infection.
• Diagnosis of long COVID according to WHO criteria.
• Participation in the baseline BioICOPER study.
• Signed informed consent for re-evaluation.

You may not qualify if…

• Acute illness preventing participation.
• Cognitive or physical impairment limiting data collection.
• Withdrawal of informed consent.
• Age < 18 years old

Where it is running

• Av. de Portugal 83. Planta 2 — Salamanca, Salamanca, Spain (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.